NCT05955183已完成1 期
Phase-1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Oral Doses in Japanese and Chinese Healthy Volunteers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Number of participants with adverse events
研究概览
简要总结
This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD5055 after single and multiple doses, orally administered in healthy Japanese and Chinese participants.
详细描述
The study will be conducted in 2 parts:
- Part 1 in single ascending dose (SAD)
- Multiple dose Eligible Japanese and Chinese participants will be randomized to receive oral dose of either AZD5055 or placebo.
The study will comprise of:
- A Screening Period of maximum 28 days.
- A Treatment Period during which participants will be resident at the Clinical Unit from the day before investigational medicinal product (IMP) administration until at least 72 hours after IMP administration.
- A Follow-up Visit within 7 ± 1 (for Part 1) and 15 ± 1 (for Part 2) days after the last IMP dose.
For the SAD part of the study, each participant will be involved in the study for 5 to 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For Chinese subjects only:
- •Participant was born in greater China, including Hong Kong, Macau, and Taiwan.
- •Participant has 2 Chinese biological parents and 4 Chinese grandparents as confirmed by interview.
- •Participant did not live outside of greater China for more than 10 years at the time of the Screening Period.
- •For Japanese subjects only:
- •Participant was born in Japan.
- •Participant has 2 Japanese biological parents and 4 Japanese grandparents as confirmed by the interview.
- •Participant did not live outside of Japan for more than 10 years at the time of the Screening Period.
- •Females must have a negative pregnancy test at the Screening Visit, must not be lactating and must be of non-childbearing potential.
- •Males must adhere to the contraception methods.
- •Have a Body mass index between 18 and 30 kg/m2 inclusive.
排除标准
- •History of any clinically significant disease or disorder which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.
- •History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- •Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study drug.
- •Any abnormal laboratory values.
- •Participants with chronic infections (eg, urinary tract infection) or who are at increased risk of infection.
- •History of cancer within the last 10 years.
- •History of osteoporosis, osteomalacia, Paget's disease of the bone, thyrotoxicosis, rheumatoid arthritis, Cushing's disease, or a pathological fracture.
- •History of traumatic fracture within 6 months of the Screening Visit.
- •Participants will be excluded if
- •In premenopausal women, men less than 50 years of age: Z-scores ≤ -2.
- •In postmenopausal women and men aged 50 years and older: T-score ≤ -2.
- •Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results.
- •Abnormal vital signs.
- •Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG.
- •History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD
- •Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days (or 5 half-lives, whichever is the longest) of the first administration of study drug in this study.
- •Has a body temperature of > 37.7°C.
- •Untreated Tuberculosis or a positive result for the Interferon gamma release assay.
- •Any positive result on Screening for serum hepatitis B surface antigen, hepatitis C antibody, and Human immunodeficiency virus.
- •History of Gilbert's syndrome.
- •History of muscle disease or rhabdomyolysis.
- •Plasma donation within one-month of the Screening Visit or any blood donation/blood loss more than 500 mL.
- •Positive screen for drugs of abuse (excluding cannabis) at Screening.
- •Current smokers who smoke > 20 cigarettes/e-cigarettes/pipes per week.
- •Use of drugs with enzyme inducing properties.
- •Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks or 5 half-lives of the medication, whichever is longer, prior to the first administration of study drug.
- •Excessive intake of caffeine-containing drinks or food.
- •Study participation by an AstraZeneca or Clinical Unit employee directly involved in the study.
- •Participants who have previously received AZD
- •Participants who have minor medical complaints which can interfere with the study data.
- •Participants who are vegans or have medical dietary restrictions.
- •Participants who cannot communicate reliably with the Investigator.
- •Vulnerable participants.
研究组 & 干预措施
AZD5055
Active Comparator
Participants will orally receive AZD5055.
干预措施: AZD5055 (Drug)
AZD5055
Active Comparator
Participants will orally receive AZD5055.
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
Participants will orally receive placebo.
干预措施: AZD5055 (Drug)
Placebo
Placebo Comparator
Participants will orally receive placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of participants with adverse events
时间窗: Until Follow-up (Day 7 ± 1 for Part 1 and Day 15 ± 1 for Part 2).
The safety and the tolerability after single and multiple doses of AZD5055 in healthy Japanese and Chinese participants will be evaluated.
次要结局
- Maximum serum concentration (Cmax)(Day 1 to Day 3 (Part 1) and Day 1 to Day 10 (Part 2))
- Area under plasma concentration-time curve from time 0 to infinity (AUCinf)(Day 1 to Day 3 (Part 1) and Day 1 to Day 10 (Part 2))
- Area under plasma concentration-curve from time 0 to the last quantifiable concentration (AUClast)(Day 1 to Day 3 (Part 1) and Day 1 to Day 10 (Part 2))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy ParticipantsHealthy ParticipantsNCT06138795AstraZeneca120
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy SubjectsDyslipidemiaNCT05384262AstraZeneca183
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy ParticipantsHealthy ParticipantsNCT06122714AstraZeneca95
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy ParticipantsRheumatoid ArthritisNCT06115967AstraZeneca40
已完成
1 期
Single Ascending Dose Study of ANX105HealthyNCT05288881Annexon, Inc.23